Pertactin-deficient Bordetella pertussis isolates

evidence of increased circulation in Europe, 1998 to 2015

Alex Mikael Barkoff, Jussi Mertsola, Denis Pierard, Tine Dalby, Silje Vermedal Hoegh, Sophie Guillot, Paola Stefanelli, Marjolein van Gent, Guy Berbers, Didrik Vestrheim, Margrethe Greve-Isdahl, Lena Wehlin, Margaretha Ljungman, Norman K. Fry, Kevin Markey, Qiushui He

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

67 Downloads (Pure)

Resumé

IntroductionPertussis outbreaks have occurred in several industrialised countries using acellular pertussis vaccines (ACVs) since the 1990s. High prevalence of pertactin (PRN)-deficient Bordetella pertussis isolates has been found in these countries.AimsTo evaluate in Europe: (i) whether proportions of PRN-deficient strains increased in consecutive collections of B. pertussis clinical isolates; (ii) if the frequency of PRN-deficient strains in countries correlated with the time since ACV introduction; (iii) the presence of pertussis toxin (PT)-, filamentous haemagglutinin (FHA)- or fimbriae (Fim)-deficient isolates.MethodsB. pertussis clinical isolates were obtained from different European countries during four periods (EUpert I-IV studies): 1998 to 2001 (n = 102), 2004 to 2005 (n = 154), 2007 to 2009 (n = 140) and 2012 to 2015 (n = 265). The isolates' selection criteria remained unchanged in all periods. PRN, PT, FHA and Fim2 and Fim3 expression were assessed by ELISA.ResultsIn each period 1.0% (1/102), 1.9% (3/154), 6.4% (9/140) and 24.9% (66/265) of isolates were PRN-deficient. In EUpert IV, PRN-deficient isolates occurred in all countries sampled and in six countries their frequency was higher than in EUpert III (for Sweden and the United Kingdom, p < 0.0001 and p = 0.0155, respectively). Sweden and Italy which used ACVs since the mid 1990s had the highest frequencies (69%; 20/29 and 55%; 11/20, respectively) while Finland, where primary immunisations with ACV containing PRN dated from 2009 had the lowest (3.6%). Throughout the study, no PT- or FHA-deficient isolate and one Fim2/3-deficient was detected.ConclusionResults suggest that the longer the period since the introduction of ACVs containing PRN, the higher the frequency of circulating PRN-deficient isolates.

OriginalsprogEngelsk
TidsskriftEurosurveillance (Print)
Vol/bind24
Udgave nummer7
ISSN1025-496X
DOI
StatusUdgivet - 14. feb. 2019

Fingeraftryk

Hemagglutinins
pertactin
Whooping Cough
Finland
Developed Countries
Patient Selection
Italy
Disease Outbreaks

Citer dette

Barkoff, Alex Mikael ; Mertsola, Jussi ; Pierard, Denis ; Dalby, Tine ; Hoegh, Silje Vermedal ; Guillot, Sophie ; Stefanelli, Paola ; van Gent, Marjolein ; Berbers, Guy ; Vestrheim, Didrik ; Greve-Isdahl, Margrethe ; Wehlin, Lena ; Ljungman, Margaretha ; Fry, Norman K. ; Markey, Kevin ; He, Qiushui. / Pertactin-deficient Bordetella pertussis isolates : evidence of increased circulation in Europe, 1998 to 2015. I: Eurosurveillance (Print). 2019 ; Bind 24, Nr. 7.
@article{d8879afe39504084bd8bda7022c14ce3,
title = "Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015",
abstract = "IntroductionPertussis outbreaks have occurred in several industrialised countries using acellular pertussis vaccines (ACVs) since the 1990s. High prevalence of pertactin (PRN)-deficient Bordetella pertussis isolates has been found in these countries.AimsTo evaluate in Europe: (i) whether proportions of PRN-deficient strains increased in consecutive collections of B. pertussis clinical isolates; (ii) if the frequency of PRN-deficient strains in countries correlated with the time since ACV introduction; (iii) the presence of pertussis toxin (PT)-, filamentous haemagglutinin (FHA)- or fimbriae (Fim)-deficient isolates.MethodsB. pertussis clinical isolates were obtained from different European countries during four periods (EUpert I-IV studies): 1998 to 2001 (n = 102), 2004 to 2005 (n = 154), 2007 to 2009 (n = 140) and 2012 to 2015 (n = 265). The isolates' selection criteria remained unchanged in all periods. PRN, PT, FHA and Fim2 and Fim3 expression were assessed by ELISA.ResultsIn each period 1.0{\%} (1/102), 1.9{\%} (3/154), 6.4{\%} (9/140) and 24.9{\%} (66/265) of isolates were PRN-deficient. In EUpert IV, PRN-deficient isolates occurred in all countries sampled and in six countries their frequency was higher than in EUpert III (for Sweden and the United Kingdom, p < 0.0001 and p = 0.0155, respectively). Sweden and Italy which used ACVs since the mid 1990s had the highest frequencies (69{\%}; 20/29 and 55{\%}; 11/20, respectively) while Finland, where primary immunisations with ACV containing PRN dated from 2009 had the lowest (3.6{\%}). Throughout the study, no PT- or FHA-deficient isolate and one Fim2/3-deficient was detected.ConclusionResults suggest that the longer the period since the introduction of ACVs containing PRN, the higher the frequency of circulating PRN-deficient isolates.",
keywords = "acellular vaccine, pertactin, pertussis, vaccination, Europe",
author = "Barkoff, {Alex Mikael} and Jussi Mertsola and Denis Pierard and Tine Dalby and Hoegh, {Silje Vermedal} and Sophie Guillot and Paola Stefanelli and {van Gent}, Marjolein and Guy Berbers and Didrik Vestrheim and Margrethe Greve-Isdahl and Lena Wehlin and Margaretha Ljungman and Fry, {Norman K.} and Kevin Markey and Qiushui He",
year = "2019",
month = "2",
day = "14",
doi = "10.2807/1560-7917.ES.2019.24.7.1700832",
language = "English",
volume = "24",
journal = "Eurosurveillance",
issn = "1025-496X",
publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",
number = "7",

}

Barkoff, AM, Mertsola, J, Pierard, D, Dalby, T, Hoegh, SV, Guillot, S, Stefanelli, P, van Gent, M, Berbers, G, Vestrheim, D, Greve-Isdahl, M, Wehlin, L, Ljungman, M, Fry, NK, Markey, K & He, Q 2019, 'Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015', Eurosurveillance (Print), bind 24, nr. 7. https://doi.org/10.2807/1560-7917.ES.2019.24.7.1700832

Pertactin-deficient Bordetella pertussis isolates : evidence of increased circulation in Europe, 1998 to 2015. / Barkoff, Alex Mikael; Mertsola, Jussi; Pierard, Denis; Dalby, Tine; Hoegh, Silje Vermedal; Guillot, Sophie; Stefanelli, Paola; van Gent, Marjolein; Berbers, Guy; Vestrheim, Didrik; Greve-Isdahl, Margrethe; Wehlin, Lena; Ljungman, Margaretha; Fry, Norman K.; Markey, Kevin; He, Qiushui.

I: Eurosurveillance (Print), Bind 24, Nr. 7, 14.02.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Pertactin-deficient Bordetella pertussis isolates

T2 - evidence of increased circulation in Europe, 1998 to 2015

AU - Barkoff, Alex Mikael

AU - Mertsola, Jussi

AU - Pierard, Denis

AU - Dalby, Tine

AU - Hoegh, Silje Vermedal

AU - Guillot, Sophie

AU - Stefanelli, Paola

AU - van Gent, Marjolein

AU - Berbers, Guy

AU - Vestrheim, Didrik

AU - Greve-Isdahl, Margrethe

AU - Wehlin, Lena

AU - Ljungman, Margaretha

AU - Fry, Norman K.

AU - Markey, Kevin

AU - He, Qiushui

PY - 2019/2/14

Y1 - 2019/2/14

N2 - IntroductionPertussis outbreaks have occurred in several industrialised countries using acellular pertussis vaccines (ACVs) since the 1990s. High prevalence of pertactin (PRN)-deficient Bordetella pertussis isolates has been found in these countries.AimsTo evaluate in Europe: (i) whether proportions of PRN-deficient strains increased in consecutive collections of B. pertussis clinical isolates; (ii) if the frequency of PRN-deficient strains in countries correlated with the time since ACV introduction; (iii) the presence of pertussis toxin (PT)-, filamentous haemagglutinin (FHA)- or fimbriae (Fim)-deficient isolates.MethodsB. pertussis clinical isolates were obtained from different European countries during four periods (EUpert I-IV studies): 1998 to 2001 (n = 102), 2004 to 2005 (n = 154), 2007 to 2009 (n = 140) and 2012 to 2015 (n = 265). The isolates' selection criteria remained unchanged in all periods. PRN, PT, FHA and Fim2 and Fim3 expression were assessed by ELISA.ResultsIn each period 1.0% (1/102), 1.9% (3/154), 6.4% (9/140) and 24.9% (66/265) of isolates were PRN-deficient. In EUpert IV, PRN-deficient isolates occurred in all countries sampled and in six countries their frequency was higher than in EUpert III (for Sweden and the United Kingdom, p < 0.0001 and p = 0.0155, respectively). Sweden and Italy which used ACVs since the mid 1990s had the highest frequencies (69%; 20/29 and 55%; 11/20, respectively) while Finland, where primary immunisations with ACV containing PRN dated from 2009 had the lowest (3.6%). Throughout the study, no PT- or FHA-deficient isolate and one Fim2/3-deficient was detected.ConclusionResults suggest that the longer the period since the introduction of ACVs containing PRN, the higher the frequency of circulating PRN-deficient isolates.

AB - IntroductionPertussis outbreaks have occurred in several industrialised countries using acellular pertussis vaccines (ACVs) since the 1990s. High prevalence of pertactin (PRN)-deficient Bordetella pertussis isolates has been found in these countries.AimsTo evaluate in Europe: (i) whether proportions of PRN-deficient strains increased in consecutive collections of B. pertussis clinical isolates; (ii) if the frequency of PRN-deficient strains in countries correlated with the time since ACV introduction; (iii) the presence of pertussis toxin (PT)-, filamentous haemagglutinin (FHA)- or fimbriae (Fim)-deficient isolates.MethodsB. pertussis clinical isolates were obtained from different European countries during four periods (EUpert I-IV studies): 1998 to 2001 (n = 102), 2004 to 2005 (n = 154), 2007 to 2009 (n = 140) and 2012 to 2015 (n = 265). The isolates' selection criteria remained unchanged in all periods. PRN, PT, FHA and Fim2 and Fim3 expression were assessed by ELISA.ResultsIn each period 1.0% (1/102), 1.9% (3/154), 6.4% (9/140) and 24.9% (66/265) of isolates were PRN-deficient. In EUpert IV, PRN-deficient isolates occurred in all countries sampled and in six countries their frequency was higher than in EUpert III (for Sweden and the United Kingdom, p < 0.0001 and p = 0.0155, respectively). Sweden and Italy which used ACVs since the mid 1990s had the highest frequencies (69%; 20/29 and 55%; 11/20, respectively) while Finland, where primary immunisations with ACV containing PRN dated from 2009 had the lowest (3.6%). Throughout the study, no PT- or FHA-deficient isolate and one Fim2/3-deficient was detected.ConclusionResults suggest that the longer the period since the introduction of ACVs containing PRN, the higher the frequency of circulating PRN-deficient isolates.

KW - acellular vaccine

KW - pertactin

KW - pertussis

KW - vaccination, Europe

U2 - 10.2807/1560-7917.ES.2019.24.7.1700832

DO - 10.2807/1560-7917.ES.2019.24.7.1700832

M3 - Journal article

VL - 24

JO - Eurosurveillance

JF - Eurosurveillance

SN - 1025-496X

IS - 7

ER -